Edoxaban
Cardiovascular - AF
Impact of frailty in patients with non-valvular atrial fibrillation undergoing catheter ablation
Soejima K, Nogami A, Kumagai K, et al.
J Arrhythmia. 2024;40(3):463-471.
Pexidartinib
Other/Multi
Real-world patient experience of pexidartinib for tenosynovial giant-cell tumor
Lin F, Kwong WJ, Pan I, et al.
Oncologist. 2024;29(4):e535-e543.
Other/Multi
Lung Cancer
Augmenting external control arms using Bayesian borrowing: A case study in first-line non-small cell lung cancer
Struebing A, McKibbon C, Ruan H, et al.
J Comp Eff Res. 2024 May;13(5):e230175.
Valemetostat
Other/Multi
Effective in vitro evaluation of the risk of histamine release related to valemetostat tosylate using MRGPRX2-expressing cells
Hamamura-Yasuno E, Kinoshita J, Goto K, et al.
J Toxicol Sci. 2024;49(4):163-174.
T-DXd
Lung Cancer
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Smit EF, Felip E, Uprety D, et al.
Lancet Oncol. 2024 Apr;25(4):439-454.
Edoxaban
Other/Multi
A disposable edoxaban sensor chip using carbon paste electrode grafted with molecularly imprinted polymer
Yoshimi Y, Kani S, Aaryashree
J Artif Organs. 2024;27(1):77-81.
T-DXd
Other/Multi
Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
Vasalou C, Proia TA, Kazlauskas L, et al.
CPT Pharmacometrics Syst Pharmacol. 2024. doi: 10.1002/psp4.13133. Epub ahead of print.
T-DXd
Breast Cancer
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
Varghese D, Cruz GI, Johanson C, et al.
Int J Clin Oncol. 2024; 29:780-789.
Other/Multi
Lung Cancer
Clinical management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: A systematic literature review
Khasraw M, Yalamanchili P, Santhanagopal A, et al.
Adv Ther. 2024;41(5):1815-1842. doi: 10.1007/s12325-024-02799-9. Epub 2024.
Edoxaban
Cardiovascular - AF
Incidence and predictors of worsening renal function in edoxaban-treated atrial fibrillation patients within ETNA-AF-Europe registry
Gwechenberger M, Barón-Esquivias G, de Vries T, et al.
JACC: Advances. 2024;3(4):100883.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26